These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39316291)

  • 1. Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China.
    Lu S; Shen L; Wang Q; Chen H; Zhao Y; Li Y; Segall G; Khanal M; Zhang X; Ding D; Shao J; Pang L
    Adv Ther; 2024 Nov; 41(11):4248-4265. PubMed ID: 39316291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
    Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
    Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
    Hess LM; Han Y; Zhu YE; Bhandari NR; Sireci A
    BMC Cancer; 2021 Jan; 21(1):28. PubMed ID: 33402119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
    Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
    Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
    Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
    Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.
    Liao D; Long M; Zhang J; Wei X; Li F; Yan T; Yang D
    Lung Cancer; 2024 Oct; 196():107936. PubMed ID: 39241296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
    Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Molecular Patterns of
    Zhang K; Chen H; Wang Y; Yang L; Zhou C; Yin W; Wang G; Mao X; Xiang J; Li B; Zhang T; Fei S
    Oncol Res; 2019 May; 27(5):575-582. PubMed ID: 30131091
    [No Abstract]   [Full Text] [Related]  

  • 14. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.
    Lu C; Wei XW; Zhang YC; Chen ZH; Xu CR; Zheng MY; Yang JJ; Zhang XC; Zhou Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2987-2995. PubMed ID: 35838839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.
    Lin C; Wang S; Xie W; Chang J; Gan Y
    Cancer Biol Ther; 2015; 16(7):1019-28. PubMed ID: 25975578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
    Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.